

**1.3 Product Information**

**1.3.1 Summary of product characteristics**

**SUMMARY OF PRODUCT CHARACTERISTICS**

**1. NAME OF THE MEDICINAL PRODUCT**

**1.1 (Invented) Name of the Medicinal Product**

Cefuroxime Axetil Tablets USP 500mg

**1.2 Strength**

Cefuroxime Axetil 500 mg

**1.3 Pharmaceutical Form**

Oral, Tablets

**2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each film coated tablet contains:

Cefuroxime Axetil (Amorphous) USP

Eq . to Cefuroxime 500 mg

Excipients q.s

Colour: Titanium Dioxide BP

Sr. No.	Ingredient	Specification	Quantity in mg/Tablet
<b>Formulation and Dispensing</b>			
1*	Cefuroxime Axetil eq to Cefuroxime	USP	*500.00
0 2**	Microcrystalline Cellulose (pH-200)	BP	**154.45
3	Magnesium Stearate	BP	4.000
4	Colloidal Anhydrous Silica	BP	5.000
5	Super D33CL	IH	35.000
6	Croscarmellose Sodium	BP	35.000
7	Doshion 544DS	IH	26.700
8	Hypromellose (E-5)	BP	10.000
9	Microcrystalline Cellulose (pH-200)	BP	82.25
10	Super-D33CL	IH	10.000
11	Croscarmellose Sodium	BP	10.000

12	Doshion 544DS	IH	15.600
<b>Lubrication</b>			
13	Magnesium Stearate	BP	6.000
14	Colloidal Anhydrous Silica	BP	6.000
<b>Coating</b>			
15	Hypromellose (E-5)	BP	4.000
16	Ethylcellulose	USP/NF	0.9000
17	Titanium Dioxide	BP	5.000
18	Hypromellose (E-15)	BP	13.500
19	Dibutyl Phthalate	BP	1.000
20	Purified Talc	BP	1.000
21	Isopropyl Alcohol	BP	121.67
22	Dichloromethane	BP	412.30

\*The quantity of API may vary depending on Potency/assay & %

LOD/water/moisture content.

\*\*The Quantity of Microcrystalline cellulose (pH-2000 may vary according API.

### 3. PHARMACEUTICAL FORM

Oral solid dosage form, Tablets

White to off white colour, oblong shape, biconvex, film coated tablet having break line on one side & other side plain.

### 4. CLINICAL PARTICULARS

#### 4.1 Therapeutic indications

Cefuroxime axetil is indicated for the treatment of the infections listed below in adults and children from the age of 3 months.

- Acute streptococcal tonsillitis and pharyngitis.
- Acute bacterial sinusitis.
- Acute otitis media.
- Acute exacerbations of chronic bronchitis.
- Cystitis
- Pyelonephritis.
- Uncomplicated skin and soft tissue infections.
- Treatment of early Lyme disease.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

**4.2 Posology and method of administration**

Posology

The usual course of therapy is seven days (may range from five to ten days).

*Table 1. Adults and children (≥40 kg)*

Indication	Dosage
Acute tonsillitis and pharyngitis, acute bacterial sinusitis	250 mg twice daily
Acute otitis media	500 mg twice daily
Acute exacerbations of chronic bronchitis	500 mg twice daily
Cystitis	250 mg twice daily
Pyelonephritis	250 mg twice daily
Uncomplicated skin and soft tissue infections	250 mg twice daily
Lyme disease	500 mg twice daily for 14 days (range of 10 to 21 days)

*Table 2. Children (<40 kg)*

Indication	Dosage
Acute tonsillitis and pharyngitis, acute bacterial sinusitis	10 mg/kg twice daily to a maximum of 125 mg twice daily
Children aged two years or older with otitis media or, where appropriate, with more severe infections	15 mg/kg twice daily to a maximum of 250 mg twice daily
Cystitis	15 mg/kg twice daily to a maximum of 250 mg twice daily
Pyelonephritis	15 mg/kg twice daily to a maximum of 250 mg twice daily for 10 to 14 days
Uncomplicated skin and soft tissue infections	15 mg/kg twice daily to a maximum of 250 mg twice daily
Lyme disease	15 mg/kg twice daily to a maximum of 250 mg twice daily for 14 days (10 to 21 days)

There is no experience of using Cefuroxime axetil in children under the age of 3 months.

*Renal impairment*

The safety and efficacy of cefuroxime axetil in patients with renal failure have not been established.

Cefuroxime is primarily excreted by the kidneys. In patients with markedly impaired renal function it is recommended that the dosage of cefuroxime should be reduced to compensate for its slower excretion. Cefuroxime is effectively removed by dialysis.

*Table 3. Recommended doses for Cefuroxime axetil in renal impairment*

Creatinine clearance	T <sub>1/2</sub> (hrs)	Recommended dosage
≥30 mL/min/1.73 m <sup>2</sup>	1.4–2.4	no dose adjustment necessary (standard dose of 125 mg to 500 mg)



		given twice daily)
10-29 mL/min/1.73 m <sup>2</sup>	4.6	standard individual dose given every 24 hours
<10 mL/min/1.73 m <sup>2</sup>	16.8	standard individual dose given every 48 hours
Patients on haemodialysis	2-4	a further standard individual dose should be given at the end of each dialysis

*Hepatic impairment*

There are no data available for patients with hepatic impairment. Since cefuroxime is primarily eliminated by the kidney, the presence of hepatic dysfunction is expected to have no effect on the pharmacokinetics of cefuroxime.

Method of administration

Oral use

Cefuroxime axetil tablets should be taken after food for optimum absorption.

**4.3 Contraindications**

Patients with known hypersensitivity to cephalosporin antibiotics.  
History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of betalactam antibacterial agent (penicillins, monobactams and carbapenems).

**4.4 Special warnings and precautions for use**

Hypersensitivity reactions

Special care is indicated in patients who have experienced an allergic reaction to penicillins or other beta-lactam antibiotics because there is a risk of cross-sensitivity. As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with cefuroxime must be discontinued immediately and adequate emergency measures must be initiated. Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to cefuroxime, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if cefuroxime is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.

Jarisch-Herxheimer reaction

The Jarisch-Herxheimer reaction has been seen following cefuroxime axetil treatment of Lyme disease. It results directly from the bactericidal activity of cefuroxime axetil on the causative bacteria of Lyme disease, the spirochaete *Borrelia burgdorferi*. Patients should be reassured that this is a common and usually self-limiting consequence of antibiotic treatment of Lyme disease (see section 4.8).

Overgrowth of non-susceptible microorganisms

As with other antibiotics, use of cefuroxime axetil may result in the overgrowth of *Candida*. Prolonged use may also result in the overgrowth of

other non-susceptible microorganisms (e.g. enterococci and *Clostridium difficile*), which may require interruption of treatment (see section 4.8). Antibacterial agent-associated pseudomembranous colitis have been reported with nearly all antibacterial agents, including cefuroxime and may range in severity from mild to life threatening. This diagnosis should be considered in patients with diarrhoea during or subsequent to the administration of cefuroxime (see section 4.8). Discontinuation of therapy with cefuroxime and the administration of specific treatment for *Clostridium difficile* should be considered. Medicinal products that inhibit peristalsis should not be given (see section 4.8).

Interference with diagnostic tests

The development of a positive Coomb's Test associated with the use of cefuroxime may interfere with cross matching of blood (see section 4.8).

As a false negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase methods are used to determine blood/plasma glucose levels in patients receiving cefuroxime axetil.

Important information about excipients

Special care should be taken with phenylketonuric patients because of the aspartame containing coating.

Cefuroxime axetil 125 mg coated tablets contain 0.2 mg aspartame per tablet.

Cefuroxime axetil 250 mg coated tablets contain 0.3 mg aspartame per tablet.

**4.5 Interaction with other medicinal products and other forms of interaction**

Drugs which reduce gastric acidity may result in a lower bioavailability of cefuroxime axetil compared with that of the fasting state and tend to cancel the effect of enhanced absorption after food.

Cefuroxime is excreted by glomerular filtration and tubular secretion.

Concomitant use of probenecid is not recommended. Concurrent administration of probenecid significantly increases the peak concentration, area under the serum concentration time curve and elimination half-life of cefuroxime.

Concomitant use with oral anticoagulants may give rise to increased INR.

**4.6 Pregnancy and lactation**

Pregnancy

There are limited data from the use of cefuroxime in pregnant women. Studies in animals have shown no harmful effects on pregnancy, embryonal or foetal development, parturition or postnatal development. Cefuroxime axetil should be prescribed to pregnant women only if the benefit outweighs the risk.

Breastfeeding

Cefuroxime is excreted in human milk in small quantities. Adverse effects at therapeutic doses are not expected, although a risk of diarrhoea and fungus infection of the mucous membranes cannot be excluded. Breastfeeding might

have to be discontinued due to these effects. The possibility of sensitisation should be taken into account. Cefuroxime should only be used during breastfeeding after benefit/risk assessment by the physician in charge.

Fertility

There are no data on the effects of cefuroxime axetil on fertility in humans. Reproductive studies in animals have shown no effects on fertility.

**4.7 Effects on ability to drive and use machines**

No studies on the effects on the ability to drive and use machines have been performed. However, as this medicine may cause dizziness, patients should be warned to be cautious when driving or operating machinery.

**4.8 Undesirable effects**

The most common adverse reactions are *Candida* overgrowth, eosinophilia, headache, dizziness, gastrointestinal disturbances and transient rise in liver enzymes.

The frequency categories assigned to the adverse reactions below are estimates, as for most reactions suitable data (for example from placebo-controlled studies) for calculating incidence were not available. In addition the incidence of adverse reactions associated with cefuroxime axetil may vary according to the indication.

Data from large clinical studies were used to determine the frequency of very common to rare undesirable effects. The frequencies assigned to all other undesirable effects (i.e. those occurring at <1/10,000) were mainly determined using post-marketing data and refer to a reporting rate rather than true frequency. Placebo-controlled trial data were not available. Where incidences have been calculated from clinical trial data, these were based on drug-related (investigator assessed) data. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Treatment related adverse reactions, all grades, are listed below by MedDRA body system organ class, frequency and grade of severity. The following convention has been utilised for the classification of frequency: very common ≥ 1/10; common ≥ 1/100 to < 1/10, uncommon ≥ 1/1,000 to < 1/100; rare ≥ 1/10,000 to < 1/1,000; very rare < 1/10,000 and not known (cannot be estimated from the available data).

System organ class	Common	Uncommon	Not known
<u>Infections and infestations</u>	<i>Candida</i> overgrowth		<i>Clostridium difficile</i> overgrowth
<u>Blood and lymphatic system disorders</u>	eosinophilia	positive Coomb's test, thrombocytopenia, leukopenia (sometimes profound)	haemolytic anaemia

<u>Immune system disorders</u>			drug fever, serum sickness, anaphylaxis, Jarisch-Herxheimer reaction
<u>Nervous system disorders</u>	headache, dizziness		
<u>Gastrointestinal disorders</u>	diarrhoea, nausea, abdominal pain	vomiting	pseudomembranous colitis
<u>Hepatobiliary disorders</u>	transient increases of hepatic enzyme levels		jaundice (predominantly cholestatic), hepatitis
<u>Skin and subcutaneous tissue disorders</u>		skin rashes	urticaria, pruritus, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (exanthematic necrolysis) (see <i>Immune system disorders</i> ), angioneurotic oedema

*Description of selected adverse reactions*

Cephalosporins as a class tend to be absorbed onto the surface of red cells membranes and react with antibodies directed against the drug to produce a positive Coombs' test (which can interfere with cross-matching of blood) and very rarely haemolytic anaemia.

Transient rises in serum liver enzymes have been observed which are usually reversible.

*Paediatric population*

The safety profile for cefuroxime axetil in children is consistent with the profile in adults.

**4.9 Overdose**

Overdose can lead to neurological sequelae including encephalopathy, convulsions and coma. Symptoms of overdose can occur if the dose is not reduced appropriately in patients with renal impairment

Serum levels of cefuroxime can be reduced by haemodialysis and peritoneal dialysis.

## 5. PHARMACOLOGICAL PROPERTIES

### 5.1 Pharmacodynamic properties

**Pharmacotherapeutic group:** Antibacterials for systemic use, second-generation cephalosporins,

**ATC code:** J01DC02,

**Mechanism of resistance:**

Cefuroxime axetil undergoes hydrolysis by esterase enzymes to the active antibiotic, cefuroxime.

Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.

Mechanism of resistance

Bacterial resistance to cefuroxime may be due to one or more of the following mechanisms:

- hydrolysis by beta-lactamases; including (but not limited to) by extended-spectrum beta-lactamases (ESBLs), and AmpC enzymes that may be induced or stably derepressed in certain aerobic Gram-negative bacteria species;
- reduced affinity of penicillin-binding proteins for cefuroxime;
- outer membrane impermeability, which restricts access of cefuroxime to penicillin binding proteins in Gram-negative bacteria;
- bacterial efflux pumps.

Organisms that have acquired resistance to other injectable cephalosporins are expected to be resistant to cefuroxime.

### 5.2 Pharmacokinetic properties

Absorption

After oral administration cefuroxime axetil is absorbed from the gastrointestinal tract and rapidly hydrolysed in the intestinal mucosa and blood to release cefuroxime into the circulation. Optimum absorption occurs when it is administered shortly after a meal.

Following administration of cefuroxime axetil tablets peak serum levels (2.9 µg/mL for a 125 mg dose, 4.4 µg/mL for a 250 mg dose, 7.7 µg/mL for a 500 mg dose and 13.6 µg/mL for a 1000 mg dose) occur approximately 2.4 hours after dosing when taken with food. The pharmacokinetics of cefuroxime is linear over the oral dosage range of 125 to 1000 mg. No accumulation of cefuroxime occurred following repeat oral doses of 250 to 500 mg.

Distribution

Protein binding has been stated as 33 to 50% depending on the methodology used. Following a single dose of cefuroxime axetil 500 mg tablet to 12 healthy volunteers, the apparent volume of distribution was 50 L (CV%=28%).

Concentrations of cefuroxime in excess of the minimum inhibitory levels for common pathogens can be achieved in the tonsilla, sinus tissues, bronchial mucosa, bone, pleural fluid, joint fluid, synovial fluid, interstitial fluid, bile,



sputum and aqueous humor. Cefuroxime passes the blood-brain barrier when the meninges are inflamed.

Biotransformation

Cefuroxime is not metabolised.

Elimination

The serum half-life is between 1 and 1.5 hours. Cefuroxime is excreted by glomerular filtration and tubular secretion. The renal clearance is in the region of 125 to 148 mL/min/1.73 m<sup>2</sup>.

Special patient populations

Gender

No differences in the pharmacokinetics of cefuroxime were observed between males and females.

Elderly

No special precaution is necessary in the elderly patients with normal renal function at dosages up to the normal maximum of 1 g per day. Elderly patients are more likely to have decreased renal function; therefore, the dose should be adjusted in accordance with the renal function in the elderly (see section 4.2).

Paediatrics population

In older infants (aged >3 months) and in children, the pharmacokinetics of cefuroxime are similar to that observed in adults.

There is no clinical trial data available on the use of cefuroxime axetil in children under the age of 3 months.

Renal impairment

The safety and efficacy of cefuroxime axetil in patients with renal failure have not been established.

Cefuroxime is primarily excreted by the kidneys. Therefore, as with all such antibiotics, in patients with markedly impaired renal function (i.e. C<sub>1cr</sub> <30 mL/minute) it is recommended that the dosage of cefuroxime should be reduced to compensate for its slower excretion (see section 4.2). Cefuroxime is effectively removed by dialysis.

Hepatic impairment

There are no data available for patients with hepatic impairment. Since cefuroxime is primarily eliminated by the kidney, the presence of hepatic dysfunction is expected to have no effect on the pharmacokinetics of cefuroxime.

PK/PD relationship

For cephalosporins, the most important pharmacokinetic-pharmacodynamic index correlating with *in vivo* efficacy has been shown to be the percentage of the dosing interval (%T) that the unbound concentration remains above the minimum inhibitory concentration (MIC) of cefuroxime for individual target species (i.e. %T>MIC).

**5.3 Preclinical safety data**

Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology, repeated dose toxicity, genotoxicity and toxicity to

reproduction and development. No carcinogenicity studies have been performed; however, there is no evidence to suggest carcinogenic potential.

Gamma glutamyl transpeptidase activity in rat urine is inhibited by various cephalosporins, however the level of inhibition is less with cefuroxime. This may have significance in the interference in clinical laboratory tests in humans

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Microcrystalline Cellulose (pH-200)  
 Magnesium Stearate  
 Colloidal Anhydrous Silica  
 Super D33CL  
 Croscarmellose Sodium  
 Doshion 544DS  
 Hypromellose (E-5)  
 Ethylcellulose  
 Titanium Dioxide  
 Hypromellose (E-15)  
 Dibutyl Phthalate  
 Purified Talc  
 Isopropyl Alcohol  
 Dichloromethane

### **6.2 Incompatibilities**

None

### **6.3 Shelf life**

24 months

### **6.4 Special precautions for storage**

Store at a temperature below 30°C in a dry place, protected from light and moisture.

### **6.5 Nature and contents of container**

Alu- Alu blister pack of 10x10 tablets packed in a carton along with package insert.

**6.6 Special precautions for disposal**

No special requirements

**7.REGISTRANT**

**MARKETING AUTHORISATION HOLDER**

**MAY & BAKER NIGERIA PLC**

3/5 Sapara Street, Industrial Estate, P.M.B.,

21049, Ikeja, Lagos, Nigeria

**MANUFACTURING SITE ADDRESS**

**ASSOCIATED BIOTECH**

Village Kishanpura,

Gurumajra Road,

Nalagarh Road, Baddi.

Tehsil Nalagarh,

Dist. Solan, H.P., India

**8. DATE OF REVISION OF THE TEXT**

10/2020